Literature DB >> 11303061

Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins.

S R Shenoy1, B R O'Keefe, A J Bolmstedt, L K Cartner, M R Boyd.   

Abstract

The virucidal protein cyanovirin-N (CV-N) mediates its highly potent anti-human immunodeficiency virus activity, at least in part, through interactions with the viral envelope glycoprotein gp120. Here we dissect in further detail the mechanism of CV-N's glycosylation-dependent binding to gp120. Isothermal titration calorimetry (ITC) binding studies of CV-N with endoglycosidase H-treated gp120 showed that binding was completely abrogated by removal of high-mannose oligosaccharides from the glycoprotein. Additional ITC and circular dichroism spectral studies with CV-N and other glycoproteins as well showed that CV-N discriminately bound only glycoproteins that contain high-mannose oligosaccharides. Binding experiments with RNase B indicated that the single high-mannose oligosaccharide on that enzyme mediated all of its binding with CV-N (K(d) = 0.602 microM). A finer level of oligosaccharide selectivity of CV-N was revealed in affinity chromatography-liquid chromatography-mass spectrometry experiments, which showed that CV-N preferentially bound only oligomannose-8 (Man-8) and oligomannose-9 isoforms of RNase B. Finally, we biophysically characterized the interaction of CV-N with a purified, single oligosaccharide, Man-8. The binding affinity of Man-8 for CV-N is unusually strong (K(d) = 0.488 microM), several hundredfold greater than observed for oligosaccharides and their protein lectins (K(d) = 1 microM--1 mM), further establishing a critical role of high-mannose oligosaccharides in CV-N binding to glycoproteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303061

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  An Update on Vaginal Microbicides.

Authors:  Christine Mauck; Gustavo Doncel
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

2.  Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile.

Authors:  Dana Huskens; Geoffrey Férir; Kurt Vermeire; Jan-Christoph Kehr; Jan Balzarini; Elke Dittmann; Dominique Schols
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

Review 3.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

4.  High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.

Authors:  Qinxue Hu; Naheed Mahmood; Robin J Shattock
Journal:  Virology       Date:  2007-07-23       Impact factor: 3.616

5.  A sugar binding protein cyanovirin-N blocks herpes simplex virus type-1 entry and cell fusion.

Authors:  Vaibhav Tiwari; Shripaad Y Shukla; Deepak Shukla
Journal:  Antiviral Res       Date:  2009-08-07       Impact factor: 5.970

6.  Designed oligomers of cyanovirin-N show enhanced HIV neutralization.

Authors:  Jennifer R Keeffe; Priyanthi N P Gnanapragasam; Sarah K Gillespie; John Yong; Pamela J Bjorkman; Stephen L Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-28       Impact factor: 11.205

7.  Multivalent glyconanoparticles with enhanced affinity to the anti-viral lectin Cyanovirin-N.

Authors:  Xin Wang; Elena Matei; Lingquan Deng; Olof Ramström; Angela M Gronenborn; Mingdi Yan
Journal:  Chem Commun (Camb)       Date:  2011-06-30       Impact factor: 6.222

8.  Sensing lectin-glycan interactions using lectin super-microarrays and glycans labeled with dye-doped silica nanoparticles.

Authors:  Xin Wang; Elena Matei; Lingquan Deng; Leonardus Koharudin; Angela M Gronenborn; Olof Ramström; Mingdi Yan
Journal:  Biosens Bioelectron       Date:  2013-03-21       Impact factor: 10.618

Review 9.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

10.  Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry.

Authors:  Bushra Yasin; Wei Wang; Mabel Pang; Natalia Cheshenko; Teresa Hong; Alan J Waring; Betsy C Herold; Elizabeth A Wagar; Robert I Lehrer
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.